THERAPEUTIC MODALITIES Archives - Page 2 of 22

Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...

High-throughput FAMA Assay to Measure Humoral Immunity against Varicella-Zoster Virus

Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...

Efficacy of a TL1A Antibody in an Acute Colitis Mouse Model

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...

Navigating the ADC Development Pathway

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....

Evaluations of Targeted Delivery Systems for RNA Therapeutics

RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations....

End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...

Integrated Platform Supporting ASO Drug Discovery

Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...